ME02145B - Radioobeleženi ligandi na bazi fenilimidazola - Google Patents
Radioobeleženi ligandi na bazi fenilimidazolaInfo
- Publication number
- ME02145B ME02145B MEP-2015-81A MEP8115A ME02145B ME 02145 B ME02145 B ME 02145B ME P8115 A MEP8115 A ME P8115A ME 02145 B ME02145 B ME 02145B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound according
- methyl
- group
- compound
- ethyl
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims 3
- SEULWJSKCVACTH-UHFFFAOYSA-N 1-phenylimidazole Chemical compound C1=NC=CN1C1=CC=CC=C1 SEULWJSKCVACTH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 claims 4
- -1 [11C] methyl Chemical group 0.000 claims 3
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005817 fluorobutyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (15)
1. Jedinjenje prema formuli Ikoje obuhvata najmanje jedan izotop odabran iz grupe koju čine 11C, 15O, i 18F, gde su R1-R7 odabrani kako sledi: a) kada je R1 radioobeležena grupa koja obuhvata najmanje jedan izotop odabran iz grupe koju čine 11C, 15O, i 18F, tada su R2-R7 pojedinačno odabrani od H, F, metil ili metoksi grupe;b) kada je jedan ili više od R2-R7 radioobeležena grupa koja obuhvata izotop odabran iz grupe koju čine 11C, 15O, i 18F, tada je R1 odabrano iz grupe koja se sastoji od H; C1-C6 alkila, kao što je metil, etil, 1-propil, 2-propil, izobutil; C1-C6 alkil (C3-C8) cikloalkila, kao što je ciklopropilmetil; C1-C6 hidroksialkila, kao što je hidroksietil; flouropropila; flourometila; i flourobutila.ili so ili hidratni oblik tog jedinjenja.
2. Jedinjenje prema zahtevu 1, u kome R3, R4, i R5 predstavljaju H, a R7 predstavlja CH3.
3. Jedinjenje prema zahtevu 1 a) i 2, u kome R2 predstavlja H, a R6 predstavlja CH3.
4. Jedinjenje prema zahtevu 3, u kome je R1 odabrano iz grupe koju čine 11CH3, -CH211CH3, -11CH2CH3, -CH2CH211CH3, -11CH2CH2CH3, -11CH2CH2CH2CH3, -CH2CH2CH211CH3, -CH2CH218F, -CH2CH2CH218F, -CH2CH2CH2CH218F.
5. Jedinjenje prema zahtevu 4, u kome R1 predstavlja 11CH3 ([11C] metil).
6. Jedinjenje prema zahtevu 1 b) i 2, u kome R1 i R6 predstavljaju CH3.
7. Jedinjenje prema zahtevu 6, u kome R2 predstavlja O11CH3 ([11C] metoksi).
8. Jedinjenje prema zahtevu 1 b) i 2, u kome R1 i R6 predstavljaju CH3.
9. Jedinjenje prema zahtevu 8, u kome R2 predstavlja 18F.
10. Jedinjenje prema zahtevu 1 b) i 2, u kome R1 predstavlja CH3, a R2 je H.
11. Jedinjenje prema zahtevu 10, u kome R6 predstavlja O11CH3 ([11C] metoksi).
12. Jedinjenje prema zahtevu 1, gde je jedinjenje odabrano iz grupe koju čine 5,8-dimetil-2-[2-([11C-1-metil]-4-fenil-1H-imidazol-2-il)-etil]-[1,2,4] triazol[1,5-a]piridin, 8-[11C] metoksi-5-metil-2-[2-(1-metil-4-fenil-1H-imidazol-2-il)-etil]-[1,2,4] triazol[1,5-a]piridin), 2-{2-[4-(2-[11C] metoksi-fenil)-1-metil-1H-imidazol-2-il]-etil}-5,8-dimetil-[1,2,4] triazol[1,5-a]piridin, i 2-{2-[4-(2-[18F]fluoro-fenil)-1-metil-1H-imidazol-2-il]-etil}-5,8-dimetil-[1,2,4] triazol[1,5-a]piridin.
13. Jedinjenje prema bilo kom od zahteva 1-12, za upotrebu kao PET ligand.
14. Jedinjenje za upotrebu prema zahtevu 13 za određivanje zauzetosti vezivanja liganda enzima PDE10A za enzim PDE10A.
15. Postupak za pripremanje jedinjenja prema bilo kom od zahteva 1 do 12.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41193410P | 2010-11-10 | 2010-11-10 | |
| DKPA201001023 | 2010-11-10 | ||
| PCT/DK2011/000132 WO2012062319A1 (en) | 2010-11-10 | 2011-11-10 | Radiolabelled phenylimidazole-based ligands |
| EP11791424.2A EP2637704B9 (en) | 2010-11-10 | 2011-11-10 | Radiolabelled phenylimidazole-based ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02145B true ME02145B (me) | 2015-10-20 |
Family
ID=45098760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-81A ME02145B (me) | 2010-11-10 | 2011-11-10 | Radioobeleženi ligandi na bazi fenilimidazola |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8592449B1 (me) |
| EP (1) | EP2637704B9 (me) |
| JP (1) | JP5820887B2 (me) |
| CN (1) | CN103732260B (me) |
| AU (1) | AU2011328598B2 (me) |
| CA (1) | CA2817385A1 (me) |
| DK (1) | DK2637704T5 (me) |
| ES (1) | ES2539464T3 (me) |
| HR (1) | HRP20150560T2 (me) |
| HU (1) | HUE025511T2 (me) |
| ME (1) | ME02145B (me) |
| PL (1) | PL2637704T4 (me) |
| PT (1) | PT2637704E (me) |
| RS (1) | RS54039B1 (me) |
| SG (1) | SG190686A1 (me) |
| SI (1) | SI2637704T1 (me) |
| SM (1) | SMT201500139B (me) |
| WO (1) | WO2012062319A1 (me) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US20150313884A1 (en) | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| EP2945633B1 (en) * | 2013-01-15 | 2021-06-30 | Novartis AG | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| EP2951176A1 (en) * | 2013-01-31 | 2015-12-09 | F. Hoffmann-La Roche AG | Radiolabeled compounds |
| WO2020094591A1 (en) | 2018-11-06 | 2020-05-14 | H. Lundbeck A/S | Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0425548D0 (en) | 2004-11-19 | 2004-12-22 | Glaxo Group Ltd | Radiolabelled ligands |
| ES2371927T3 (es) | 2005-01-13 | 2012-01-11 | Ge Healthcare Limited | Compuestos de bencil-lactama marcados con 11c y su uso como agentes de obtención de imágenes. |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| EP2036578A1 (en) | 2007-09-13 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | Diagnostic agents for positron emission imaging using F-18 radio labeled amino-alcohols |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| WO2010097367A1 (en) * | 2009-02-24 | 2010-09-02 | Janssen Pharmaceutica Nv | Radiolabelled pde10 ligands |
-
2011
- 2011-11-10 HR HRP20150560TT patent/HRP20150560T2/hr unknown
- 2011-11-10 CN CN201180054508.4A patent/CN103732260B/zh not_active Expired - Fee Related
- 2011-11-10 RS RS20150367A patent/RS54039B1/sr unknown
- 2011-11-10 US US13/890,705 patent/US8592449B1/en not_active Expired - Fee Related
- 2011-11-10 PT PT117914242T patent/PT2637704E/pt unknown
- 2011-11-10 WO PCT/DK2011/000132 patent/WO2012062319A1/en not_active Ceased
- 2011-11-10 JP JP2013538069A patent/JP5820887B2/ja not_active Expired - Fee Related
- 2011-11-10 DK DK11791424.2T patent/DK2637704T5/en active
- 2011-11-10 HU HUE11791424A patent/HUE025511T2/en unknown
- 2011-11-10 ME MEP-2015-81A patent/ME02145B/me unknown
- 2011-11-10 EP EP11791424.2A patent/EP2637704B9/en active Active
- 2011-11-10 SG SG2013035134A patent/SG190686A1/en unknown
- 2011-11-10 CA CA2817385A patent/CA2817385A1/en not_active Abandoned
- 2011-11-10 PL PL11791424T patent/PL2637704T4/pl unknown
- 2011-11-10 AU AU2011328598A patent/AU2011328598B2/en not_active Ceased
- 2011-11-10 ES ES11791424.2T patent/ES2539464T3/es active Active
- 2011-11-10 SI SI201130518T patent/SI2637704T1/sl unknown
-
2015
- 2015-06-16 SM SM201500139T patent/SMT201500139B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SMT201500139B (it) | 2015-09-07 |
| CN103732260A (zh) | 2014-04-16 |
| JP5820887B2 (ja) | 2015-11-24 |
| CA2817385A1 (en) | 2012-05-18 |
| DK2637704T3 (da) | 2015-06-22 |
| EP2637704A1 (en) | 2013-09-18 |
| HK1189498A1 (en) | 2014-06-13 |
| EP2637704B9 (en) | 2015-08-05 |
| US8592449B1 (en) | 2013-11-26 |
| PL2637704T3 (pl) | 2015-08-31 |
| HRP20150560T2 (hr) | 2015-11-20 |
| SG190686A1 (en) | 2013-07-31 |
| HUE025511T2 (en) | 2016-04-28 |
| SI2637704T1 (sl) | 2015-07-31 |
| DK2637704T5 (en) | 2015-09-21 |
| JP2013543851A (ja) | 2013-12-09 |
| AU2011328598A1 (en) | 2013-05-30 |
| PL2637704T4 (pl) | 2015-08-31 |
| ES2539464T3 (es) | 2015-07-01 |
| EP2637704B1 (en) | 2015-03-25 |
| RS54039B1 (sr) | 2015-10-30 |
| US20130303770A1 (en) | 2013-11-14 |
| CN103732260B (zh) | 2018-08-10 |
| HRP20150560T1 (xx) | 2015-07-03 |
| AU2011328598B2 (en) | 2016-04-21 |
| PT2637704E (pt) | 2015-07-21 |
| WO2012062319A1 (en) | 2012-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150560T2 (hr) | Radiooznaäśeni ligandi na bazi fenilimidazola | |
| ME02193B (me) | Derivati imidazola kao inhibitori enzima pde10a | |
| HRP20201727T1 (hr) | 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino)pirido[2,3-d]pirimidin-7(8h)-on derivati i srodni spojevi kao cdk4 inhibitori za liječenje tumora | |
| HRP20110289T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| HRP20140632T1 (hr) | Derivati 2-arimidazola kao inhibitori pde10a enzima | |
| HRP20191091T1 (hr) | Inhibitor fosfoinozitid-3-kinaze s ostatkom koji se veže na cink | |
| JP2012531433A5 (me) | ||
| DE602007009839D1 (de) | Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika | |
| PE20091819A1 (es) | DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA | |
| HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
| HRP20170028T1 (hr) | Derivat morfolinonukleinske kiseline | |
| FR19C1033I2 (fr) | Derives phosphores servant d'inhibiteurs de kinase | |
| ZA201000832B (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| TN2009000149A1 (en) | 2- [l-phenyl-5-hydroxy-4 alpha-methyl-hexahydrocyclopenta [f] indazol-5-yl] ethyl phenyl derivatives as glucocorticoid receptor ligands | |
| JP2010504286A5 (me) | ||
| HRP20100516T1 (hr) | Tiazolpirazolopirimidini kao antagonisti receptora crf1 | |
| JP2013542963A5 (me) | ||
| MY157676A (en) | Diphenyl-pyrazolopyridine derivatives,preparation thereof, and use thereof as nuclear receptor not modulators | |
| WO2008006625A3 (en) | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | |
| EP3388426A3 (en) | Compounds for protection of cells | |
| MX2010008686A (es) | Derivado de pirrolopirimidina como inhibidor de fosfatidilinositol 3-quinasa y uso del mismo. | |
| MX2010004234A (es) | Derivados de purina como ligandos del receptor de adenosina a1. | |
| HRP20121026T1 (hr) | Postupak za dobivanje kaspofungina i njegovih intermedijera | |
| WO2011092719A3 (en) | Process for preparing 1 -phenyl-3 -dimethylaminopropane derivatives | |
| HRP20241128T1 (hr) | Postupak sinteze eliglustata i njegovih intermedijarnih spojeva |